Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of “Hold” by Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given a consensus recommendation of “Hold” by the twenty-three research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $104.4211.

Several brokerages have weighed in on ZBH. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. Zacks Research raised Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group reiterated a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group increased their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $99.40 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $18.96 billion, a PE ratio of 24.19, a P/E/G ratio of 2.76 and a beta of 0.45. The firm has a fifty day simple moving average of $93.63 and a two-hundred day simple moving average of $91.38. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $106.88.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts expect that Zimmer Biomet will post 8.54 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at about $204,000. Sivia Capital Partners LLC bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $232,000. United Bank increased its holdings in Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after acquiring an additional 1,153 shares in the last quarter. Federated Hermes Inc. raised its stake in Zimmer Biomet by 129.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after acquiring an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its holdings in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.